Strategies of polymeric nanoparticles for enhanced internalization in cancer therapy
Source abstract
Abstract
In order to achieve long circulation time and high drug accumulation in the tumor sites via the EPR effects, anticancer drugs have to be protected by non-fouling polymers such as poly(ethylene glycol) (PEG), poly(ethylene oxide) (PEO), dextran, and poly(acrylic acid) (PAA). However, the dense layer of stealth polymer also prohibits efficient uptake of anticancer drugs by target cancer cells. For cancer therapy, it is often more desirable to accomplish rapid cellular uptake after anticancer drugs arriving at the pathological site, which could on one hand maximize the therapeutic efficacy and on the other hand reduce probability of drug resistance in cells. In this review, special attention will be focused on the recent potential strategies that can enable drug-loaded polymeric nanoparticles to rapidly recognize cancer cells, leading to enhanced internalization.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Long-circulating and target-specific nanoparticles: theory to practice10.1016/S0031-6997(24)01494-7 ↗
2. Nanoparticle therapeutics: an emerging treatment modality for cancer10.1038/nrd2614 ↗
3. Tumour-targeted nanomedicines: principles and practice10.1038/sj.bjc.6604483 ↗
4. Strategies in the design of nanoparticles for therapeutic applications10.1038/nrd2591 ↗
5. Drug delivery using multifunctional dendrimers and hyperbranched polymers10.1517/17425247.2010.534981 ↗
6. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery10.1016/j.jconrel.2010.08.027 ↗
7. Nanopreparations for organelle-specific delivery in cancer10.1016/j.addr.2013.11.004 ↗
8. Impact of nanotechnology on drug delivery10.1021/nn900002m ↗
9. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
10. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies10.1158/1078-0432.CCR-03-0655 ↗
11. A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer
12. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin10.1038/sj.bjc.6602204 ↗
13. Delivering nanomedicine to solid tumors10.1038/nrclinonc.2010.139 ↗
14. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress10.1016/j.jconrel.2011.09.063 ↗
15. Tumor delivery of macromolecular drugs based on the EPR effect10.1016/j.addr.2010.03.011 ↗
16. Polymeric micelles drug delivery system in oncology10.1016/j.jconrel.2011.12.012 ↗
17. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma10.1016/j.addr.2010.09.001 ↗
18. Sheddable coatings for long-circulating nanoparticles10.1007/s11095-007-9348-7 ↗
19. Cancer nanotechnology: opportunities and challenges10.1038/nrc1566 ↗
20. Multidrug resistance in cancer: role of ATP-dependent transporters10.1038/nrc706 ↗
21. Fluoxetine and reversal of multidrug resistance10.1016/j.canlet.2005.06.003 ↗
22. Transferrin receptors in human tissues: their distribution and possible clinical relevance10.1136/jcp.36.5.539 ↗
23. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models10.1158/0008-5472.CAN-05-4199 ↗
24. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging10.1073/pnas.0707461104 ↗
25. Multifunctional HER2-antibody conjugated polymeric nanocarrier-based drug delivery system for multi-drug-resistant breast cancer therapy10.1021/am406012g ↗
26. EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy10.1016/j.biomaterials.2013.06.007 ↗
27. Antibody fragment-conjugated polymeric micelles incorporating platinum drugs for targeted therapy of pancreatic cancer10.1016/j.biomaterials.2014.10.069 ↗
28. Improved therapeutic effect of DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18 F(ab′)(2) for hepatocellular carcinoma10.1021/bm1005992 ↗
29. Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes10.1186/1477-3155-11-19 ↗
30. Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy10.1016/j.biomaterials.2012.09.064 ↗
31. Aptamer-nanoparticle bioconjugates enhance intracellular delivery of vinorelbine to breast cancer cells10.3109/1061186X.2013.839683 ↗
32. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo10.1016/j.jconrel.2014.10.018 ↗
33. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia10.1158/1078-0432.CCR-12-3191 ↗
34. Lactoferrin-modified poly(ethylene glycol)-grafted BSA nanoparticles as a dual-targeting carrier for treating brain gliomas10.1021/mp500238m ↗
35. RGD peptide-modified multifunctional dendrimer platform for drug encapsulation and targeted inhibition of cancer cells
36. Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier10.1021/nn402662d ↗
37. iRGD conjugated TPGS mediates codelivery of paclitaxel and survivin shRNA for the reversal of lung cancer resistance10.1021/mp400576f ↗
38. LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor10.1016/j.jconrel.2011.07.034 ↗
39. Folic acid conjugated cross-linked acrylic polymer (FA-CLAP) hydrogel for site specific delivery of hydrophobic drugs to cancer cells10.1186/1477-3155-12-25 ↗
40. Polymersomes conjugated with des-octanoyl ghrelin and folate as a BBB-penetrating cancer cell-targeting delivery system10.1016/j.biomaterials.2014.01.042 ↗
41. Galactose-decorated reduction-sensitive degradable chimaeric polymersomes as a multifunctional nanocarrier to efficiently chaperone apoptotic proteins into hepatoma cells10.1021/bm4007248 ↗
42. Photo-crosslinked hyaluronic acid nanoparticles with improved stability for in vivo tumor-targeted drug delivery10.1016/j.biomaterials.2013.03.050 ↗
43. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile10.1126/scitranslmed.3003651 ↗
44. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation10.1039/c2cs15344k ↗
45. Controlled antibody/(bio-) conjugation of inorganic nanoparticles for targeted delivery10.1016/j.addr.2012.12.003 ↗
46. Universal antibody conjugation to nanoparticles using the Fcgamma receptor I (FcgammaRI): quantitative profiling of membrane biomarkers10.1021/bc5003778 ↗
47. Actively targeted cetuximab conjugated gamma-poly(glutamic acid)-docetaxel nanomedicines for epidermal growth factor receptor over expressing colon cancer cells10.1166/jbn.2014.1841 ↗
48. Antibody conjugated PLGA nanoparticles for targeted delivery of paclitaxel palmitate: efficacy and biofate in a lung cancer mouse model10.1002/smll.201301417 ↗
49. Biodegradable nanoparticles for direct or two-step tumor immunotargeting10.1021/bc050137k ↗
50. Poly(lactic acid) nanoparticles labeled with biologically active Neutravidin for active targeting10.1016/j.ejpb.2004.04.006 ↗
51. Single-antibody, targeted nanoparticle delivery of camptothecin, Mol
52. Targeted nanoparticles assembled via complexation of boronic-acid-containing targeting moieties to diol-containing polymers10.1021/bc300640j ↗
53. Biological characterization of cetuximab-conjugated gold nanoparticles in a tumor animal model10.1088/0957-4484/25/29/295102 ↗
54. Preclinical safety testing of biotechnology-derived pharmaceuticals10.1385/MB:27:1:59 ↗
55. Nanocarriers as an emerging platform for cancer therapy10.1038/nnano.2007.387 ↗
56. Antibody-conjugated nanoparticles for therapeutic applications10.2174/092986712800784667 ↗
57. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer10.1093/annonc/mdh092 ↗
58. Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts10.1111/j.1349-7006.2004.tb02495.x ↗
59. Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors10.1038/mt.2013.32 ↗
60. Suppression of pancreatic tumor growth by targeted arsenic delivery with anti-CD44v6 single chain antibody conjugated nanoparticles10.1016/j.biomaterials.2013.04.056 ↗
61. Orlova · 2007 · 63
62. High-affinity binding to staphylococcal protein A by an engineered dimeric Affibody molecule10.1093/protein/gzt038 ↗
63. Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition10.2967/jnumed.111.101527 ↗
64. Active targeting using HER-2-affibody-conjugated nanoparticles enabled sensitive and specific imaging of orthotopic HER-2 positive ovarian tumors10.1002/smll.201301593 ↗
65. Nanobubble-affibody: novel ultrasound contrast agents for targeted molecular ultrasound imaging of tumor10.1016/j.biomaterials.2014.10.013 ↗
66. Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL)10.1021/bc900061v ↗
67. Affibody modified and radiolabeled gold-iron oxide hetero-nanostructures for tumor PET, optical and MR imaging10.1016/j.biomaterials.2013.01.014 ↗
68. Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles10.1016/j.biomaterials.2013.10.001 ↗
69. GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics,10.1016/j.tips.2014.03.003 ↗
70. Targeting tumors with nanobodies for cancer imaging and therapy10.1016/j.jconrel.2013.08.298 ↗
71. Intraoperative fluorescence delineation of head and neck cancer with a fluorescent anti-epidermal growth factor receptor nanobody10.1002/ijc.28601 ↗
72. A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis10.1186/bcr3585 ↗
73. Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells10.1016/j.jconrel.2012.11.007 ↗
74. Array-based discovery of aptamer pairs
75. SELEX—a (r) evolutionary method to generate high-affinity nucleic acid ligands10.1016/j.bioeng.2007.06.001 ↗
76. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase10.1126/science.2200121 ↗
77. In vitro selection of RNA molecules that bind specific ligands10.1038/346818a0 ↗
78. Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges10.7150/thno.9663 ↗
79. Polyvalent nucleic acid aptamers and modulation of their activity: a focus on the thrombin binding aptamer10.1016/j.pharmthera.2012.07.011 ↗
80. Nucleic acid aptamer-mediated drug delivery for targeted cancer therapy
81. Targeted nanoparticles for cancer therapy10.1016/S1748-0132(07)70083-X ↗
82. Molecular diagnostic and drug delivery agents based on aptamer-nanomaterial conjugates10.1016/j.addr.2010.03.003 ↗
83. Aptamer database10.1093/nar/gkh094 ↗
84. Aptamer nanomedicine for cancer therapeutics: barriers and potential for translation10.1021/nn507494p ↗
85. Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys10.1016/S0378-4347(99)00285-6 ↗
86. Pegaptanib for neovascular age-related macular degeneration10.1056/NEJMoa042760 ↗
87. Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy10.1016/j.jconrel.2013.06.006 ↗
88. A theranostic “SMART” aptamer for targeted therapy of prostate cancer10.1038/mt.2014.190 ↗
89. Targeting tumor vasculature with aptamer-functionalized Doxorubicin-polylactide nanoconjugates for enhanced cancer therapy10.1021/acsnano.5b00166 ↗
90. Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas10.1016/j.biomaterials.2014.01.019 ↗
91. The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research10.1016/j.urolonc.2013.09.003 ↗
92. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo10.1073/pnas.1011379108 ↗
93. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy10.1073/pnas.1011368107 ↗
94. An ultra pH-sensitive and aptamer-equipped nanoscale drug-delivery system for selective killing of tumor cells10.1002/smll.201202694 ↗
95. Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells
96. Whole-cell SELEX aptamer-functionalised poly(ethyleneglycol)-poly(epsilon-caprolactone) nanoparticles for enhanced targeted glioblastoma therapy10.1016/j.biomaterials.2012.05.020 ↗
97. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles10.1073/pnas.0914140107 ↗
98. Blood-brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins10.1007/978-1-4615-0123-7_15 ↗
99. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic,10.1021/mp900015y ↗
100. Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA10.1073/pnas.1411393111 ↗